TITLE

MEDIMMUNE AND ABPRO ENTER INTO AGREEMENT

PUB. DATE
January 2017
SOURCE
Biotech Business;Jan2017, Vol. 30 Issue 1, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the collaborative agreement signed by MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, pioneer of industrial biochemistry, to advance the development of bispecific antibody that targets angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). It says that AbMed, the subsidiary of Abpro, will receive the majority global development and commercialization rights while MedImmune will receive royalties and majority equity stake.
ACCESSION #
120540014

 

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics